Squamous cell skin cancer

Sirnaomics to Present at TIDES Europe 2021

Retrieved on: 
Tuesday, November 16, 2021

and SUZHOU BIOBAY, China, Nov. 16, 2021 /PRNewswire/ -- Sirnaomics, Inc. , a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announcedthat it will be presenting positive results from a Phase 2a clinical study of the company's lead drug candidate, STP705, for treatment of squamous cell skin cancer in situ(nonmelanoma skin cancer) at the 2021 TIDES Europe event.

Key Points: 
  • and SUZHOU BIOBAY, China, Nov. 16, 2021 /PRNewswire/ -- Sirnaomics, Inc. , a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announcedthat it will be presenting positive results from a Phase 2a clinical study of the company's lead drug candidate, STP705, for treatment of squamous cell skin cancer in situ(nonmelanoma skin cancer) at the 2021 TIDES Europe event.
  • The hybrid conference is taking place digitally and in person at the Sheraton Brussels Airport Hotel in Belgium from November 15-17, 2021.
  • Sirnaomics, Inc., a leading privately held biopharmaceutical company for discovery and development of RNAi therapeutics, is aDelawarecorporation headquartered inGaithersburg, Maryland, with subsidiaries in Suzhou andGuangzhou, China.
  • Sirnaomics has developed a strong portfolio of intellectual property with an enriched product pipeline.

Sirnaomics, Inc. to Present at TIDES USA 2021

Retrieved on: 
Wednesday, September 22, 2021

The hybrid conference is taking place in person at the Boston Convention and Exhibition Center, and digitally on-demand, September 20-30.

Key Points: 
  • The hybrid conference is taking place in person at the Boston Convention and Exhibition Center, and digitally on-demand, September 20-30.
  • Presenter: Michael Molyneaux, MD, MBA, Chief Medical Officer at Sirnaomics, Inc.
  • Time/Date: 11:45am ET, Thursday, September 23, 2021.
  • The session will be available to watch on demand for attendees starting on September 28 for a 30-day period.

Castle Biosciences Presents New Data Demonstrating DecisionDx®-SCC Complements Current Risk Assessment Methods in Patients with Cutaneous Squamous Cell Carcinoma of the Head and Neck

Retrieved on: 
Friday, July 23, 2021

DecisionDx-SCC is Castles prognostic 40-gene expression profile (GEP) test for patients diagnosed with high-risk cutaneous squamous cell carcinoma (SCC), designed to use a patients tumor biology to predict individual risk of metastasis for patients with SCC and one or more risk factors.

Key Points: 
  • DecisionDx-SCC is Castles prognostic 40-gene expression profile (GEP) test for patients diagnosed with high-risk cutaneous squamous cell carcinoma (SCC), designed to use a patients tumor biology to predict individual risk of metastasis for patients with SCC and one or more risk factors.
  • The data further demonstrate that Castles DecisionDx-SCC test can provide clinicians with additional information on a patients metastatic risk to help them make more informed choices about their treatment and follow-up care.
  • All SCC tumor specimens were tested with DecisionDx-SCC and analyzed using Kaplan-Meier for metastasis-free survival (MFS) and Cox regression for risk of regional/distant metastasis.
  • DecisionDx-SCC is a 40-gene expression profile test that uses an individual patients tumor biology to predict individual risk of cutaneous squamous cell carcinoma metastasis for patients with one or more risk factors.

Topical MEK Inhibitor, NFX-179, Prevents Cutaneous Squamous Cell Carcinoma in Pre-Clinical Model

Retrieved on: 
Tuesday, May 4, 2021

Near-complete suppression of cutaneous squamous cell carcinoma was observed only in the drug-treated area, demonstrating the targeted and local effect of the drug candidate.

Key Points: 
  • Near-complete suppression of cutaneous squamous cell carcinoma was observed only in the drug-treated area, demonstrating the targeted and local effect of the drug candidate.
  • "\nCutaneous squamous cell carcinoma is one of the most common cancers, with an estimated 700,000 cases diagnosed in the United States annually.
  • Risk factors for cutaneous squamous cell carcinoma include older age, male sex, fair pigmentation, ultraviolet exposure and immunosuppression.
  • NFlection is working to address RASopathies through the development of first-in-class soft MEK (mitogen-activated protein kinase kinase) inhibitors as topical treatments to mitigate or treat cutaneous neurofibromas in neurofibromatosis type 1, congenital birthmarks and immunosuppressant-mediated squamous cell carcinoma.

2021 Global Squamous Cell Carcinoma Epidemiology and Patient Flow Report - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 4, 2021

b'The "Global Squamous Cell Carcinoma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report provides Squamous Cell Carcinoma epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Squamous Cell Carcinoma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report provides Squamous Cell Carcinoma epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Squamous Cell Carcinoma patients, history of the disease at the population level (Squamous Cell Carcinoma prevalence, Squamous Cell Carcinoma incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nSquamous Cell Carcinoma patient flow: Squamous Cell Carcinoma prevalence, diagnosed, and drug-treated patients\nDemographics: Squamous Cell Carcinoma patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Squamous Cell Carcinoma market sizing, assessing market potential, and developing drug forecast models\nIdentify Squamous Cell Carcinoma patients segments through age groups, gender, and disease sub-types\nEvaluate Squamous Cell Carcinoma market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210504005637/en/\n'

Global Cutaneous Squamous Cell Carcinoma Treatment Market to Surpass US$ 16,867.06 Million by 2027, Says Coherent Market Insights (CMI)

Retrieved on: 
Wednesday, December 16, 2020

Key trends in the market include rising incidence of cutaneous squamous cell carcinoma treatment and ongoing research and development for the treatment of cutaneous squamous-cell carcinoma.

Key Points: 
  • Key trends in the market include rising incidence of cutaneous squamous cell carcinoma treatment and ongoing research and development for the treatment of cutaneous squamous-cell carcinoma.
  • Market players are actively focusing on research and development for Cutaneous Squamous Cell Carcinoma Treatment for cost effective and quality treatment.
  • The global cutaneous squamous cell carcinoma treatment market is expected to exhibit a CAGR of 7.2% during the forecast period, owing to rising incidence of cutaneous squamous-cell carcinoma globally.
  • Global Cutaneous Squamous Cell Carcinoma Treatment Market, By Treatment:

Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

Retrieved on: 
Thursday, September 17, 2020

At the time of analysis, 114 patients with advanced cancers had been treated with cosibelimab and were evaluable for safety.

Key Points: 
  • At the time of analysis, 114 patients with advanced cancers had been treated with cosibelimab and were evaluable for safety.
  • Cosibelimab appeared to be safe and well-tolerated with a potentially favorable safety profile as compared to currently available anti-PD-1 therapies.
  • The trial continues to enroll patients, and full top-line results are expected in mid-2021.
  • Cutaneous squamous cell carcinoma (CSCC) is the second most common human cancer in the United States, with an estimated annual incidence of 700,000 cases.

New Data Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-SCC Test Results on Patient Management Decisions

Retrieved on: 
Tuesday, May 19, 2020

The article titled, Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma, was published in the peer-reviewed journal, Current Medical Research and Opinion (CMRO).

Key Points: 
  • The article titled, Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma, was published in the peer-reviewed journal, Current Medical Research and Opinion (CMRO).
  • Results of the study demonstrate that integration of DecisionDx-SCC (40-gene expression profile test) results impacted management decisions in a significant and risk-appropriate manner for high-risk SCC patient scenarios, while remaining aligned with national guidelines for patient management.
  • These results demonstrate that information on tumor biology can impact clinical decisions in a significant, risk-appropriate manner.
  • They were then asked to rate clinicopathological features and DecisionDx-SCC test results to assess their opinion of how concerning each is to SCC prognosis.

 Castle Biosciences Announces Publication of Validation Study for DecisionDx-SCC, Showing this Test is an Independent Predictor of Metastatic Risk in Squamous Cell Carcinoma

Retrieved on: 
Wednesday, April 29, 2020

The study results demonstrate that DecisionDx-SCC is an independent predictor of metastatic risk that can complement current cancer risk-factor staging systems for patients with high-risk SCC.

Key Points: 
  • The study results demonstrate that DecisionDx-SCC is an independent predictor of metastatic risk that can complement current cancer risk-factor staging systems for patients with high-risk SCC.
  • Validation of the DecisionDx-SCC test demonstrates significant progress in this area by integrating tumor-specific genetic information into clinical decision making.
  • SCC National Comprehensive Cancer Network (NCCN) guidelines define treatment pathways based on risk of local recurrence or metastasis.
  • For SCC, there are two clinicopathologically defined categories: low risk and high risk.

Castle Biosciences Announces Study Establishing the Value of Integrating DecisionDx-SCC Test into Management of High-Risk Cutaneous Squamous Cell Carcinoma

Retrieved on: 
Monday, January 20, 2020

The poster titled, Integrating the 40-Gene Expression Profile (40-GEP) Test into Management of High-Risk Cutaneous Squamous Cell Carcinoma, was presented during the 2020 Winter Clinical Dermatology Conference, January 17-22 in Hawaii.

Key Points: 
  • The poster titled, Integrating the 40-Gene Expression Profile (40-GEP) Test into Management of High-Risk Cutaneous Squamous Cell Carcinoma, was presented during the 2020 Winter Clinical Dermatology Conference, January 17-22 in Hawaii.
  • Approximately 1 million patients are diagnosed with cutaneous SCC in the U.S. each year, and the incidence continues to grow.
  • The data support a framework for risk-aligned treatment plans when DecisionDx-SCC is incorporated into management of NCCN high-risk cutaneous SCC patients.
  • Cutaneous squamous cell carcinoma (SCC), a nonmelanoma skin cancer, is one of the most common cancers.